MedTrace Logo

Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis

NCT00962741 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2014-06-10

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of etanercept on the clinical benefit, safety, and physical functioning (ability to function in daily life) in children and adolescent subjects with 3 subtypes of childhood arthritis.

Conditions

  • Arthritis, Juvenile Idiopathic

Interventions

DRUG

Etanercept

Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-06-30
Completion
2013-01-31

Countries

  • Australia
  • Belgium
  • Colombia
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Latvia
  • Lithuania
  • Mexico
  • Netherlands
  • Norway
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • Slovenia
  • Spain

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00962741 on ClinicalTrials.gov